TY - JOUR
T1 - Coffee consumption and risk of colorectal cancer in the Cancer Prevention Study-II Nutrition Cohort
AU - Um, Caroline Y.
AU - McCullough, Marjorie L.
AU - Guinter, Mark A.
AU - Campbell, Peter T.
AU - Jacobs, Eric J.
AU - Gapstur, Susan M.
N1 - Funding Information:
The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II Nutrition Cohort.
Funding Information:
The authors express sincere appreciation to all Cancer Prevention Study-II Nutrition Cohort participants and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the National Cancer Institute's Surveillance Epidemiology and End Results Program.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/8
Y1 - 2020/8
N2 - Background: The association between coffee consumption and colorectal cancer risk generally appears null, but recent evidence suggests that risk may vary by coffee type. We examined associations of caffeinated and decaffeinated coffee intake with colorectal cancer risk overall and with colon and rectum separately, among older U.S. men and women. Methods: In 1999, 47,010 men and 60,051 women with no previous diagnosis of cancer, aged 47–96 years, in the Cancer Prevention Study-II Nutrition Cohort completed a food frequency questionnaire that assessed caffeinated and decaffeinated coffee intake; consumption was updated in 2003. A total of 1829 colorectal cancer cases were verified through June 2015. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard rate ratios (HRs) and 95% confidence intervals (CIs), adjusting for smoking history, alcohol, caffeinated/decaffeinated coffee intake (depending on the model), and other colorectal cancer risk factors. Results: Consumption of ≥2 cups/day of decaffeinated coffee, compared to no decaffeinated coffee, was associated with lower risk of overall colorectal cancer (HR = 0.82, 95% CI: 0.69−0.96, P-trend = 0.04), colon cancer (HR = 0.82, 95% CI: 0.69−0.99, P-trend = 0.05) and rectal cancer (HR = 0.63, 95% CI: 0.40−0.99, P-trend = 0.17). Consumption of ≥2 cups/day of caffeinated coffee was associated with higher risk of rectal cancer (HR = 1.37, 95% CI: 0.99–1.89, P-trend = 0.04), but not with colorectal or colon cancer. Conclusion: In this prospective study, higher intake of decaffeinated coffee was associated with lower risk of colorectal, colon, and rectal cancers. Further study on associations of caffeinated and decaffeinated coffee with colorectal cancer risk by subsite is needed.
AB - Background: The association between coffee consumption and colorectal cancer risk generally appears null, but recent evidence suggests that risk may vary by coffee type. We examined associations of caffeinated and decaffeinated coffee intake with colorectal cancer risk overall and with colon and rectum separately, among older U.S. men and women. Methods: In 1999, 47,010 men and 60,051 women with no previous diagnosis of cancer, aged 47–96 years, in the Cancer Prevention Study-II Nutrition Cohort completed a food frequency questionnaire that assessed caffeinated and decaffeinated coffee intake; consumption was updated in 2003. A total of 1829 colorectal cancer cases were verified through June 2015. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard rate ratios (HRs) and 95% confidence intervals (CIs), adjusting for smoking history, alcohol, caffeinated/decaffeinated coffee intake (depending on the model), and other colorectal cancer risk factors. Results: Consumption of ≥2 cups/day of decaffeinated coffee, compared to no decaffeinated coffee, was associated with lower risk of overall colorectal cancer (HR = 0.82, 95% CI: 0.69−0.96, P-trend = 0.04), colon cancer (HR = 0.82, 95% CI: 0.69−0.99, P-trend = 0.05) and rectal cancer (HR = 0.63, 95% CI: 0.40−0.99, P-trend = 0.17). Consumption of ≥2 cups/day of caffeinated coffee was associated with higher risk of rectal cancer (HR = 1.37, 95% CI: 0.99–1.89, P-trend = 0.04), but not with colorectal or colon cancer. Conclusion: In this prospective study, higher intake of decaffeinated coffee was associated with lower risk of colorectal, colon, and rectal cancers. Further study on associations of caffeinated and decaffeinated coffee with colorectal cancer risk by subsite is needed.
KW - Caffeine
KW - Coffee
KW - Cohort study
KW - Colorectal cancer
KW - Colorectal subsite
UR - http://www.scopus.com/inward/record.url?scp=85085948514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085948514&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2020.101730
DO - 10.1016/j.canep.2020.101730
M3 - Article
C2 - 32526644
AN - SCOPUS:85085948514
SN - 1877-7821
VL - 67
JO - Cancer Epidemiology
JF - Cancer Epidemiology
M1 - 101730
ER -
